Prevention of aneurysm development and rupture by local overexpression of plasminogen activator inhibitor-1

Circulation

Volumn 98, Issue 3, 1998, Pages 249-255

  Allaire, Eric ^c   Hasenstab, David ^a   Kenagy, Richard D ^a   Starcher, Barry ^b   Clowes, Monika M ^a   Clowes, Alexander W ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Department of Biochemistry   (France)

^c HENRI MONDOR HOSPITAL   (France)

Author keywords

Aneurysm; Genes; Metalloproteinases; Plasminogen activators; Transplantation

Indexed keywords

METALLOPROTEINASE; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ANEURYSM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; GUINEA PIG; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION;

EID: 0032555097     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.98.3.249     Document Type: Article

References (65)

1. Dobrin PB, Baker WH, Gley WC. Elastolytic and collagenolytic studies of arteries: implications for the mechanical properties of aneurysms. Arch Surg. 1984;119:405-409.
2. Anidjar S, Kieffer E. Pathogenesis of acquired aneurysms of the abdominal aorta. Ann Vasc Surg. 1992;6:298-305.
3. MacSweeney ST, Powell JT, Greenhalgh RM. Pathogenesis of abdominal aortic aneurysm. Br J Surg. 1994;81:935-941.
4. Brophy CM, Reilly JM, Smith GJ, Tilson MD. The role of inflammation in nonspecific abdominal aortic aneurysm disease. Ann Vasc Surg. 1991; 5:229-233.
5. Koch AE, Haines GK, Rizzo RJ, Radosevich JA, Pope RM, Robinson PG, Pearce WH. Human abdominal aortic aneurysms: immunopathologic analysis suggesting an immune-mediated response. Am J Pathol. 1990; 137:1199-1213.
6. Jean Claude J, Newman KM, Li H, Gregory AK, Tilson MD. Possible key role for plasmin in the pathogenesis of abdominal aortic aneurysms. Surgery. 1994;116:472-478.
7. Reilly JM, Sicard GA, Lucore CL. Abnormal expression of plasminogen activators in aortic aneurysmal and occlusive disease. J Vasc Surg. 1994; 19:865-872.
8. Schneiderman J, Bordin GM, Engelberg I, Adar R, Seiffert D, Thinnes T, Bernstein EF, Dilley RB, Loskutoff DJ. Expression of fibrinolytic genes in atherosclerotic abdominal aortic aneurysm wall: a possible mechanism for aneurysm expansion. J Clin Invest. 1995;96:639-645.
9. Vine N, Powell JT. Metalloproteinases in degenerative aortic disease. Clin Sci. 1991;81:233-239.
10. Newman KM, Ogata Y, Malon AM, Irizarry E, Gandhi RH, Nagase H, Tilson MD. Identification of matrix metalloproteinases 3 (stromelysin-1) and 9 (gelatinase B) in abdominal aortic aneurysm. Arterioscler Thromb. 1994;14:1315-1320.
11. Thompson RW, Holmes DR, Mertens RA, Liao S, Botney MD, Mecham RP. Welgus HG, Parks WC. Production and localization of 92-kilodalton gelatinase in abdominal aortic aneurysms: an elastolytic metalloproteinase expressed by aneurysm-infiltrating macrophages. J Clin Invest. 1995;96:318-326.
12. McMillan WD, Patterson BK, Keen RR, Shively VP, Cipollone M, Pearce WH. In situ localization and quantification of mRNA for 92-kD type IV collagenase and its inhibitor in aneurysmal, occlusive, and normal aorta. Arterioscler Thromb Vasc Biol. 1995;15:1139-1144.
13. Irizarry E, Newman KM, Gandhi RH, Nackman GB, Halpern V, Wishner S, Scholes JV. Demonstration of interstitial collagenase in abdominal aortic aneurysm disease. J Surg Res. 1993;54:571-574.
14. Newman KM, Jean Claude J, Li H, Scholes JV, Ogata Y, Nagase H. Cellular localization of matrix metalloproteinases in the abdominal aortic aneurysm wall. J Vasc Surg. 1994;20:814-820.
15. Deleted in proof.
16. Anidjar S, Salzmann JL, Gentric D, Lagneau P, Camilleri JP, Michel JB. Elastase-induced experimental aneurysm in rat. Circulation. 1990;82: 973-981.
17. Nagase H, Enghild JJ, Suzuki K, Salvesen G. Stepwise activation mechanisms of the precursor of matrix metalloproteinase 3 (stromelysin) by proteinases and (4-aminophenyl)mercuric acetate. Biochemistry. 1990;29: 5783-5789.
18. He CS, Wilhelm SM, Pentland AP, Marmer BL, Grant GA, Eisen AZ, Goldberg GI. Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc Natl Acad Sci U S A. 1989;86: 2632-2636.
19. Ogata Y, Itoh Y, Nagase H. Steps involved in activation of the pro-matrix metalloproteinase 9 (progelatinase B)-tissue inhibitor of metalloproteinases-1 complex by 4-aminophenylmercuric acetate and proteinases. J Biol Chem. 1995;270:18506-18511.
20. Shapiro SD, Fliszar CJ, Broekelmann TJ, Mecham RP, Senior RM, Welgus HG. Activation of the 92-kDa gelatinase by stromelysin and 4-aminophenylmercuric acetate: differential processing and stabilization of the carboxyl-terminal domain by tissue inhibitor of metalloproteinases (TIMP). J Biol Chem. 1995;270:6351-6356.
21. Baramova EN, Bajou K, Remade JM, L'Hoir C, Krell HW, Weidle UH, Noel A, Foidart JM. Involvement of PA/plasmin system in the processing of pro-MMP-9 and in the second step of pro-MMP-2 activation. FEBS Lett. 1997;405:157-162.
22. Mazzieri R, Masiero L, Zanetta L, Monea S, Onisto M, Garbisa S, Mignatti P. Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. EMBO J. 1997;16:2319-2332.
23. Allaire E, Guettier C, Bruneval P, Plissonnier D, Michel JB. Cell-free arterial grafts: morphologic characteristics of aortic isografts, allografts, and xenografts in rats. J Vasc Surg. 1994;19:446-456.
24. Allaire E, Bruneval P, Mandet C, Becquemin JP, Michel JB. The immunogenicity of the arterial extracellular matrix in arterial xenografts. Surgery. 1997;122:73-81.
25. Allaire E, Forough R, Wang T, Clowes MM, Clowes AW. Tissue metalloproteinase inhibitor-1 (TIMP-1) overexpression prevents arterial rupture and dilation in a xenograft model. FASEB J. 1996;10:A1134. Abstract.
26. Lynch CM, Clowes MM, Osborne WR, Clowes AW, Miller AD. Long-term expression of human adenosine deaminase in vascular smooth muscle cells of rats: a model for gene therapy. Proc Natl Acad Sci U S A. 1992;89:1138-1142.
27. Zeheb R, Gelehrter TD. Cloning and sequencing of cDNA for the rat plasminogen activator inhibitor-1. Gene. 1988;73:459-468.
28. Miller AD, Rosman GJ. Improved retroviral vectors for gene transfer and expression. Biotechniques. 1989;7:980-989.
29. Starcher B, Conrad M. A role for neutrophil elastase in the progression of solar elastosis. Connect Tissue Res. 1995;31:133-140.
30. Camiolo SM, Siuta MR, Madeja JM. Improved medium for extraction of plasminogen activator from tissue. Prep Biochem. 1982;12:297-305.
31. Clowes AW, Clowes MM, Au YPT, Reidy MA. Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid artery. Circ Res. 1990;67:61-67.
32. Zehr BD, Savin TJ, Hall RE. A one-step, low background Coomassie staining procedure for polyacrylamide gels. Anal Biochem. 1989;182: 157-159.
33. Abramson SR, Conner GE, Nagase H, Neuhaus I, Woessner JFJ. Characterization of rat uterine matrilysin and its cDNA: relationship to human pump-1 and activation of procollagenases. J Biol Chem. 1995;270: 16016-16022.
34. Eitzman DT, Fay WP, Lawrence DA, Francis Chmura AM, Shore JD, Olson ST, Ginsburg D. Peptide-mediated inactivation of recombinant and platelet plasminogen activator inhibitor-1 in vitro. J Clin Invest. 1995; 95:2416-2420.
35. Plow EF, Herrer T, Redlitz A, Miles LA, Hoover-Plow JL. The cell biology of the plasminogen system. FASEB J. 1995;9:939-945.
36. Ossowski L. Invasion of connective tissue by human carcinoma cell lines: requirement for urokinase, urokinase receptor, and interstitial collagenase. Cancer Res. 1992;52:6754-6760.
37. Clowes AW, Clowes MM, Kirkman TR, Jackson CL, Au YPT, Kenagy RD. Heparin inhibits the expression of tissue-type plasminogen activator by smooth muscle cells in injured rat carotid artery. Circ Res. 1992;70: 1128-1136.
38. Kenagy RD, Vergel S, Mattsson E, Bendeck M, Reidy MA, Clowes AW. The role of plasminogen, plasminogen activators, and matrix metalloproteinases in primate arterial smooth muscle cell migration. Arterioscler Thromb Vasc Biol. 1996;16:1373-1382.
39. Libby P. Molecular bases of the acute coronary syndromes. Circulation. 1995;91:2844-2850.
40. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994;94: 2493-2503.
41. Nikkari ST, O'Brien KD, Ferguson M, Hatsukami T, Welgus HG, Alpers CE, Clowes AW. Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis. Circulation. 1995;92:1393-1398.
42. Nikkari ST, Geary RL, Hatsukami T, Ferguson M, Forough R, Alpers CE, Clowes AW. Expression of collagenase, and tissue inhibitor of metalloproteinase-1 in restenosis after carotid endarterectomy. Am J Pathol. 1996;148:777-783.
43. Raghunath PN, Tomaszewski JE, Brady ST, Caron RJ, Okada SS, Barnathan ES. Plasminogen activator system in human coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 1995;15:1432-1443.
44. Lupu F, Heim DA, Bachmann F, Hurni M, Kakkar VV, Kruithof EK. Plasminogen activator expression in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 1995;15:1444-1455.
45. Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, Loskutoff DJ. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci U S A. 1992;89:6998-7002.
46. Carmeliet P, Moons L, Lijnen R, Baes M, Lemaître V, Tipping P, Drew A, Eeckhout Y, Lupu F, Collen D. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet. 1997; 17:439-444.
47. Mueller BM, Yu YB, Laug WE. Overexpression of plasminogen activator inhibitor 2 in human melanoma cells inhibits spontaneous metastasis in scid/scid mice. Proc Natl Acad Sci U S A. 1995;92:205-209.
48. Bjorquist P, Brohlin M, Ehnebom J, Ericsson M, Kristiansen C, Pohl G, Deinum J. Plasminogen activator inhibitor type-1 interacts exclusively with the proteinase domain of tissue plasminogen activator. Biochim Biophys Acta. 1994;1209:191-202.
49. Loskutoff DJ, Sawdey M, Mimuro J. Type 1 plasminogen activator inhibitor. Prog Hemost Thromb 1989;9:87-115.
50. Wagner OF, de Vries C, Hohmann C, Veerman H, Pannekoek H. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA): binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA. J Clin Invest. 1989;84:647-655.
51. Hekman CM, Loskutoff DJ. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J Biol Chem. 1985;260:11581-11587.
52. Simpson AJ, Booth NA, Moore NR, Bennett B. Distribution of plasminogen activator inhibitor (PAI-1) in tissues. J Clin Pathol. 1991;44: 139-143.
53. Lawrance DA, Loskutoff DJ. Inactivation of plasminogen activator inhibitor by oxidants. Biochemistry. 1986;25:6351-6355.
54. Chapman HA, Reilly JJ, Kobzik L. Role of plasminogen activator in the degradation of extracellular matrix protein by live human alveolar macrophages. Am Rev Respir Dis. 1988;137:412-419.
55. Montgomery AM, De Clerck YA, Langley KE, Reisfeld RA, Mueller BM. Melanoma-mediated dissolution of extracellular matrix: contribution of urokinase-dependent and metalloproteinase-dependent proteolytic pathways. Cancer Res. 1993;53:693-700.
56. Murphy G, Cockett MI, Ward RV, Docherty AJ. Matrix metalloproteinase degradation of elastin, type IV collagen and proteoglycan: a quantitative comparison of the activities of 95 kDa and 72 kDa gelatinases, stromelysins-1 and -2 and punctuated metalloproteinase (PUMP). Biochem J. 1991;277:277-279.
57. Senior RM, Griffin GL, Fliszar CJ, Shapiro SD, Goldberg GI, Welgus HG. Human 92- and 72-kilodalton type IV collagenases are elastases. J Biol Chem. 1995;266:7870-7875.
58. Katsuda S, Okada Y, Imai K, Nakanishi I. Matrix metalloproteinase-9 (92-kd gelatinase/type IV collagenase equals gelatinase B) can degrade arterial elastin. Am J Pathol. 1994;145:1208-1218.
59. Okada Y, Morodomi T, Enghild JJ, Suzuki K, Yasui A, Nakanishi I, Salvesen G, Nagase H. Matrix metalloproteinase 2 from human rheumatoid synovial fibroblasts: purification and activation of the precursor and enzymic properties. Eur J Biochem. 1990;194:721-730.
60. Mecham RP, Broekelmann TJ, Fliszar CJ, Shapiro SD, Welgus HG, Senior RM. Elastin degradation by matrix metalloproteinases: cleavage site specificity and mechanisms of elastolysis. J Biol Chem. 1997;272: 18071-18076.
61. Shipley JM, Doyle GAR, Fliszar CJ, Ye QZ, Johnson LL, Shapiro SD, Welgus HG, Senior RM. The structural basis for the elastinolytic activity of the 92-kDa and 72 kDa gelatinases. J Biol Chem. 1996;8:4335-4341.
62. Birkedal-Hansen H, Moore WGI, Bodden MK, Windsor LJ, Birkedal-Hansen B, DeCarlo A, Engler JA. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med. 1993;4:197-250.
63. Okada Y, Nagase H, Harris EDJ. A metalloproteinase from human rheumatoid synovial fibroblasts that digests connective tissue matrix components: purification and characterization. J Biol Chem. 1986;261: 14245-14255.
64. Okada Y, Harris EDJ, Nagase H. The precursor of a metalloendopeptidase from human rheumatoid synovial fibroblasts: purification and mechanisms of activation by endopeptidases and 4-aminophenylmercuric acetate. Biochem J. 1988;254:731-741.
65. Okada Y, Gonoji Y, Naka K, Tomita K, Nakanishi I, Iwata K, Yamashita K, Hayakawa T. Matrix metalloproteinase 9 (92-kDa gelatinase/type IV collagenase) from HT 1080 human fibrosarcoma cells: purification and activation of the precursor and enzymic properties. J Biol Chem. 1992; 267:21712-21719.